Clinical Trials Browser

OTHER × Carcinoma, Non-Small-Cell Lung × camrelizumab × Clear all

NCT06241807 2024-02-14

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04379739 2023-12-06

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05825443 2023-04-25

PANORAMA

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05532527 2022-09-08

NSCLC

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung

NCT04291092 2021-09-10

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04943029 2021-09-02

NEOSUN

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04950400 2021-07-06

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung

NCT04541251 2021-06-23

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04828395 2021-05-11

F&C

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04793139 2021-03-11

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Carcinoma, Non-Small-Cell Lung

NCT04768075 2021-02-24

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04631146 2020-11-17

Efficacy and Safety of Camrelizumab in Real-World Study

Carcinoma, Non-Small-Cell Lung

NCT04303130 2020-03-10

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03557411 2020-02-05

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04167774 2019-11-22

Compass-001

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04108013 2019-09-27

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03527251 2018-05-30

SEQUENCE

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung